Key result
Vericiguat demonstrates therapeutic potential to prevent post-MI HF by restoring NO-sGC-cGMP signaling.
Why the study?
Current therapies for reperfusion and clinical guidelines cannot fully prevent heart failure after myocardial infarction, necessitating investigation of molecular mechanisms and new treatments.
Vericiguat represents a potential paradigm shift from treating established heart failure to proactively preventing adverse cardiac remodeling in the early post-myocardial infarction period.
No takes yet. Share an insight, caveat, or question.
Further mechanistic studies on NO-sGC-cGMP signaling in post-MI HF are needed; leaves open therapeutic targeting pending prospective trials.
Atajanova et al. (2026) conducted a review in Post-Myocardial Infarction Heart Failure. Vericiguat was evaluated. Vericiguat, an oral soluble guanylate cyclase stimulator, demonstrates therapeutic potential for preventing post-myocardial infarction heart failure by restoring the NO-sGC-cGMP signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: